Reuters logo
BRIEF-PDL Biopharma unit receives Paragraph IV notice letter
June 5, 2017 / 10:51 AM / 4 months ago

BRIEF-PDL Biopharma unit receives Paragraph IV notice letter

June 5 (Reuters) - Pdl Biopharma Inc

* Says announced that its subsidiary, noden pharma dac received a paragraph iv notice letter

* Pdl biopharma - letter advised that anchen pharmaceuticals submitted an abbreviated new drug application to u.s. Fda

* Pdl biopharma - anchen sought fda authorization to manufacture and market generic tekturna aliskiren hemifumarate tablets, 150 mg and 300 mg, in u.s. Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below